Hence, an important question arises: Whether biochemical markers that are widely tested during the first trimester of pregnancy in terms of screening for aneuploidies, such as placental growth factor (PlGF) and plasma-associated protein-A (PAPP-A), could also be included in the recommendations for GDM screening? Here, PAPPA is linked to gestational diabetes.